Literature DB >> 9055038

Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3'-exonuclease.

M Koziołkiewicz1, M Wójcik, A Kobylańska, B Karwowski, B Rebowska, P Guga, W J Stec.   

Abstract

The stability of stereoregular oligo(nucleoside phosphorothioate)s (PS-oligos) in human plasma has been studied. 3'-Exonuclease present in human plasma appeared to be RP specific, that is, it cleaves internucleotide phosphorothioate linkages of [RP]-configuration and not those of [SP]-configuration. Therefore, PS-oligos containing all phosphorothioate internucleotide linkages of [RP]-configuration [RP-PS-oligos]) are more effectively degraded by the enzyme than PS-oligos prepared via nonstereo-controlled methods (so-called random mixture of diastereomers [Mix-PS-oligos]), whereas oligo(nucleoside phosphorothioate)s of [S(P)]-configuration remain intact. The enzyme activity depends on the sequence of nucleobases. The presence of deoxycytidine units (three or more residues) at the 3'-end of PS-oligo substrate significantly inhibits the enzyme activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9055038     DOI: 10.1089/oli.1.1997.7.43

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  16 in total

1.  Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages.

Authors:  W Brad Wan; Michael T Migawa; Guillermo Vasquez; Heather M Murray; Josh G Nichols; Hans Gaus; Andres Berdeja; Sam Lee; Christopher E Hart; Walt F Lima; Eric E Swayze; Punit P Seth
Journal:  Nucleic Acids Res       Date:  2014-11-14       Impact factor: 16.971

2.  Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry.

Authors:  Xiaohui Wei; Guowei Dai; Zhongfa Liu; Hao Cheng; Zhiliang Xie; Guido Marcucci; Kenneth K Chan
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

3.  Radiolabeled oligonucleotides for antisense imaging.

Authors:  Arun K Iyer; Jiang He
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

4.  Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.

Authors:  Naoki Iwamoto; David C D Butler; Nenad Svrzikapa; Susovan Mohapatra; Ivan Zlatev; Dinah W Y Sah; Stephany M Standley; Genliang Lu; Luciano H Apponi; Maria Frank-Kamenetsky; Jason Jingxin Zhang; Chandra Vargeese; Gregory L Verdine
Journal:  Nat Biotechnol       Date:  2017-08-21       Impact factor: 54.908

5.  A direct comparison of anti-microRNA oligonucleotide potency.

Authors:  Kim A Lennox; Mark A Behlke
Journal:  Pharm Res       Date:  2010-04-28       Impact factor: 4.200

6.  Chloroplast ribonuclease P does not utilize the ribozyme-type pre-tRNA cleavage mechanism.

Authors:  B C Thomas; X Li; P Gegenheimer
Journal:  RNA       Date:  2000-04       Impact factor: 4.942

Review 7.  Antisense technology: A review.

Authors:  Stanley T Crooke; Xue-Hai Liang; Brenda F Baker; Rosanne M Crooke
Journal:  J Biol Chem       Date:  2021-02-16       Impact factor: 5.157

8.  Histidine triad nucleotide-binding protein 1 (HINT-1) phosphoramidase transforms nucleoside 5'-O-phosphorothioates to nucleoside 5'-O-phosphates.

Authors:  Magdalena Ozga; Rafal Dolot; Magdalena Janicka; Renata Kaczmarek; Agnieszka Krakowiak
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

Review 9.  Crystallographic studies of chemically modified nucleic acids: a backward glance.

Authors:  Martin Egli; Pradeep S Pallan
Journal:  Chem Biodivers       Date:  2010-01       Impact factor: 2.408

10.  Significance of stereochemistry of 3'-terminal phosphorothioate-modified primer in DNA polymerase-mediated chain extension.

Authors:  Barbara Nawrot; Natasha Paul; Beata Rebowska; Wojciech J Stec
Journal:  Mol Biotechnol       Date:  2008-09-04       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.